Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial
BackgroundIn this trial, we aimed to assess the efficacy and safety of radiotherapy with nedaplatin or cisplatin in patients with locally advanced cervical cancer.MethodsWe conducted an open-label, non-inferiority, phase III, randomized, controlled trial. Eligible patients with stage IIB-IVA cervica...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.798617/full |
| _version_ | 1819294775543595008 |
|---|---|
| author | Shasha He Yan Wang Yulin Lai Xinping Cao Yufeng Ren Yong Chen |
| author_facet | Shasha He Yan Wang Yulin Lai Xinping Cao Yufeng Ren Yong Chen |
| author_sort | Shasha He |
| collection | DOAJ |
| description | BackgroundIn this trial, we aimed to assess the efficacy and safety of radiotherapy with nedaplatin or cisplatin in patients with locally advanced cervical cancer.MethodsWe conducted an open-label, non-inferiority, phase III, randomized, controlled trial. Eligible patients with stage IIB-IVA cervical carcinoma were randomly assigned to receive either nedaplatin or cisplatin for two cycles concurrently with radiotherapy. We reported the therapy-associated harms and survival. The study was registered with chictr.org.cn, number ChiCTR1800020527.ResultsWe randomly assigned 68 patients to nedaplatin-based or cisplatin-based concurrent chemoradiotherapy. Study treatment was stopped early after a data analysis found a higher number of patients suffered severe hematologic harms in the nedaplatin group than in the cisplatin group. Patients in the nedaplatin group had a significantly higher frequency of grade 3-4 neutropenia (19·4% vs. 13%; P < 0·001), severe thrombocytopenia (16·1% vs. 4·3%), and grade 1-2 anemia (51·6% vs. 43·5%) than patients in the cisplatin group. The 1-year PFS and OS in the nedaplatin and cisplatin groups were similar.ConclusionOur findings showed that nedaplatin-based concurrent chemoradiotherapy expressed remarkably higher severe hematologic harms which were mortal. Though the results were negative, the experiences and lessons we learned from it were important. |
| first_indexed | 2024-12-24T04:31:41Z |
| format | Article |
| id | doaj.art-36110399f0fe432ea2f6838e21ce4e3f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-24T04:31:41Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-36110399f0fe432ea2f6838e21ce4e3f2022-12-21T17:15:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-02-011110.3389/fonc.2021.798617798617Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III TrialShasha He0Yan Wang1Yulin Lai2Xinping Cao3Yufeng Ren4Yong Chen5Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, ChinaBackgroundIn this trial, we aimed to assess the efficacy and safety of radiotherapy with nedaplatin or cisplatin in patients with locally advanced cervical cancer.MethodsWe conducted an open-label, non-inferiority, phase III, randomized, controlled trial. Eligible patients with stage IIB-IVA cervical carcinoma were randomly assigned to receive either nedaplatin or cisplatin for two cycles concurrently with radiotherapy. We reported the therapy-associated harms and survival. The study was registered with chictr.org.cn, number ChiCTR1800020527.ResultsWe randomly assigned 68 patients to nedaplatin-based or cisplatin-based concurrent chemoradiotherapy. Study treatment was stopped early after a data analysis found a higher number of patients suffered severe hematologic harms in the nedaplatin group than in the cisplatin group. Patients in the nedaplatin group had a significantly higher frequency of grade 3-4 neutropenia (19·4% vs. 13%; P < 0·001), severe thrombocytopenia (16·1% vs. 4·3%), and grade 1-2 anemia (51·6% vs. 43·5%) than patients in the cisplatin group. The 1-year PFS and OS in the nedaplatin and cisplatin groups were similar.ConclusionOur findings showed that nedaplatin-based concurrent chemoradiotherapy expressed remarkably higher severe hematologic harms which were mortal. Though the results were negative, the experiences and lessons we learned from it were important.https://www.frontiersin.org/articles/10.3389/fonc.2021.798617/fullcervical carcinomanedaplatincisplatintoxicitysurvival |
| spellingShingle | Shasha He Yan Wang Yulin Lai Xinping Cao Yufeng Ren Yong Chen Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial Frontiers in Oncology cervical carcinoma nedaplatin cisplatin toxicity survival |
| title | Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial |
| title_full | Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial |
| title_fullStr | Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial |
| title_full_unstemmed | Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial |
| title_short | Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial |
| title_sort | concurrent chemoradiotherapy with nedaplatin versus cisplatin in patients with stage iib iva cervical cancer a randomized phase iii trial |
| topic | cervical carcinoma nedaplatin cisplatin toxicity survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.798617/full |
| work_keys_str_mv | AT shashahe concurrentchemoradiotherapywithnedaplatinversuscisplatininpatientswithstageiibivacervicalcancerarandomizedphaseiiitrial AT yanwang concurrentchemoradiotherapywithnedaplatinversuscisplatininpatientswithstageiibivacervicalcancerarandomizedphaseiiitrial AT yulinlai concurrentchemoradiotherapywithnedaplatinversuscisplatininpatientswithstageiibivacervicalcancerarandomizedphaseiiitrial AT xinpingcao concurrentchemoradiotherapywithnedaplatinversuscisplatininpatientswithstageiibivacervicalcancerarandomizedphaseiiitrial AT yufengren concurrentchemoradiotherapywithnedaplatinversuscisplatininpatientswithstageiibivacervicalcancerarandomizedphaseiiitrial AT yongchen concurrentchemoradiotherapywithnedaplatinversuscisplatininpatientswithstageiibivacervicalcancerarandomizedphaseiiitrial |